{"id":"NCT02547935","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","officialTitle":"An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-09-21","primaryCompletion":"2018-05-18","completion":"2018-05-18","firstPosted":"2015-09-14","resultsPosted":"2019-06-04","lastUpdate":"2019-08-21"},"enrollment":459,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus, CKD and Albuminuria"],"interventions":[{"type":"DRUG","name":"Dapagliflozin 10 mg","otherNames":["Forxiga™"]},{"type":"DRUG","name":"Saxagliptin 2.5 mg","otherNames":["Onglyza™"]},{"type":"DRUG","name":"Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg","otherNames":[]}],"arms":[{"label":"Dapagliflozin 10mg","type":"EXPERIMENTAL"},{"label":"Dapagliflozin 10mg + Saxagliptin 2.5mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Dapagliflozin 10 mg + Saxagliptin 2.5 mg","deltaMin":-0.85,"sd":0.09},{"arm":"Placebo","deltaMin":-0.27,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":112,"countries":["United States","Australia","Canada","Japan","Mexico","South Africa","South Korea","Spain","Taiwan"]},"refs":{"pmids":["38770818","38017482","30992195"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3763&filename=D1690c00023_CSP_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3763&filename=D1690c00023_SAP_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":152},"commonTop":["Nasopharyngitis","Influenza"]}}